IXICO PLC - London-based neuroscience data analytics company - Says 2022 revenue will decrease by GBP300,000 after Huntington's disease study contract canceled by client. The study had been using IXICO's safety and data analysis service to support the understanding of findings, in an open-label extension after phase three trials ended. The contract was due to run for three more years. The company's order book now totals GBP12.6 million, including the loss from the cancellation.
IXICO says it has a "strong pipeline of opportunities" with the client, who is designing a new phase two clinical trial for the investigative drug for the treatment of Huntingdon's disease.
Current stock price: 52.54 pence, down 9.4% on Thursday
12-month change: down 41%
By Elizabeth Winter; elizabethwinter@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.
Ixico (IXI)